Flu remedies: out in the cold

Published By Datamonitor

GW Pharmaceuticals: high expectations for cannabis drug

GW Pharmaceuticals [GWP.L] and Bayer Healthcare [BAY.F] have submitted a New Drug Submission for Sativex, a cannabis-based medicine for the symptomatic treatment of multiple sclerosis (MS) and neuropathic pain, to Health Canada. This move will help generate optimism regarding Sativex, offering renewed hope for manufacturers and patients alike.

Published By Datamonitor

ID Biomedical: prevention is better than cure

If ID's Streptococcus vaccine proves to be effective, it has a strong chance of commercial success. There is a strong opportunity to develop vaccines for bacterial disease, as vaccination is considered preferable to antibiotic treatment. ID is at a particular advantage in this area, due to its Proteosomes nasal drug delivery technology.

Published By Datamonitor

Inex/GSK: the growing importance of drug delivery

GSK will foot the bill for Inex's development work. In a market where drug delivery is becoming as important as the compound itself, the deal represents a good chance for GSK to boost the sales and life expectancy of its drug. Inex, meanwhile, should gain significant opportunities by partnering with a leading pharmaceutical company.

Published By Datamonitor

Sanofi-Aventis/Apotex: olive branch acceptance to reduce generic threat

Sanofi-Aventis and Bristol-Myers Squibb have reached an agreement to settle a patent infringement suit with Canadian generics maker Apotex over the anti-platelet agent Plavix. As well as enabling the companies to avoid court proceedings, the settlement should delay the generic threat to Plavix - a possibility the pharma heavyweights' investors have already embraced judging by share price surges.

Published By Datamonitor

Sanofi-Aventis/BMS: a Plavix plague on both their houses?

Canadian generics firm Apotex has received an approval from the FDA to launch a generic version of Sanofi-Aventis and Bristol-Myers Squibb's blockbuster heart drug Plavix. This is bad, although expected, news for the two pharma giants, which both need to stave off such generic threats. However, the companies are not going down without a fight, as Sanofi-Aventis' patent infringement filing shows.

Published By Datamonitor